Medical Research News

RSS

Scripps Research study findings could transform drug development to produce more effective treatments

Scientists from The Scripps Research Institute have uncovered new evidence that challenges the current theory about a process key to the way modern drugs are designed and how they work in the human body.

12 Oct 2010

Researchers develop new method to identify chemical histone modifications

Test system on Drosophila should provide the key to histone function. The genetic inherited material DNA was long viewed as the sole bearer of hereditary information. The function of its packaging proteins, the histones, was believed to be exclusively structural. Additional genetic information can be stored, however, and passed on to subsequent generations through chemical changes in the DNA or histones. Scientists from the Max Planck Institute for Biophysical Chemistry in Göttingen have succeeded in creating an experimental system for testing the function of such chemical histone modifications and their influence on the organism.

12 Oct 2010

Physical and psychological factors contribute to somatic symptoms: Report

Patients with cancer who experience pain or depression also have a high rate of physical symptoms, such as fatigue, dry mouth and nausea, according to a report in the October 11 issue of Archives of Internal Medicine, one of the JAMA/Archives journals.

12 Oct 2010

Halozyme Therapeutics to advance core proprietary programs through key clinical inflection points

Halozyme Therapeutics, Inc., a biopharmaceutical company developing and commercializing products targeting the extracellular matrix, today announced a focusing of its resources on advancing its core proprietary programs through key clinical inflection points in 2011 and 2012, and supporting strategic alliances with Roche and Baxter such as validation of Halozyme's commercial scale manufacturing process to produce kilogram quantities of enzyme.

12 Oct 2010

Working mothers lose favor in a population study

According to a study by Janeen Baxter, professor of sociology at the University of Queensland, Australians are less inclined to believe a working mother can be as good a mother as one who stays at home full-time and they believe if the husband is the main breadwinner and the wife cares for home and children, it works for the best.

12 Oct 2010

Helmets to prevent rising off-road bike crashes

According to a new study Australia's off-road motorbike riders need to wear helmets more often. Research has shown that off-road crashes resulting in death or serious injury was the only rising category among Victoria's motorcycle community from 2001 to 2008. The results showed that the death toll from all motorcycle crashes plateaued over the period and this masked an almost doubling of the death and injuries which occurred off-road.

12 Oct 2010

Insulin resistance increases risk of stroke in non-diabetic patients

Insulin resistance, a condition in which insulin produced by the body becomes less effective in reducing blood glucose levels, appears to be associated with an increased risk of stroke in individuals without diabetes, according to a report in the October issue of Archives of Neurology, one of the JAMA/Archives journals.

12 Oct 2010

Study: Neurons interact to drive decision-making

We know that casting a ballot in the voting booth involves politics, values and personalities. But before you ever push the button for your candidate, your brain has already carried out an election of its own to make that action possible. New research from Vanderbilt University reveals that our brain accumulates evidence when faced with a choice and triggers an action once that evidence reaches a tipping point.

12 Oct 2010

$Balloon kyphoplasty relieves painful spine fractures in patients with metastatic cancer$

Balloon kyphoplasty relieves painful spine fractures in patients with metastatic cancer

A surgical technique appears to offer quick and effective relief for debilitating spinal fractures often suffered by patients with metastatic cancer, researchers reported at the 35th Congress of the European Society for Medical Oncology (ESMO) in Milan.

11 Oct 2010

New targeted therapy adds benefit to erlotinib in some patients with advanced lung cancer

A subset of lung cancer patients seem to live longer and experience delays in disease progression when a new drug that targets a cancer-associated molecule called MET is added to treatment with erlotinib, the results of a double-blind Phase-II trial show.

11 Oct 2010

Erlotinib improves progression-free survival as first-line therapy in advanced lung cancer

For patients with advanced lung cancer whose tumors carry EGFR activating mutations, first-line treatment with erlotinib nearly tripled progression-free survival compared to a standard chemotherapy combination, show results from the first prospective Phase-III study to report findings in this setting.

11 Oct 2010

Identifying subsets of patients who will respond to subsequent lines of chemotherapy

In a study presented at the 35th Congress of the European Society for Medical Oncology (ESMO), Dr Giovanni Bernardo from Fondazione Maugeri in Pavia, Italy, presented results that suggested it may be possible to identify subsets of metastatic breast cancer patients who are likely to respond to subsequent lines of chemotherapy.

11 Oct 2010

Phase 3 study shows everolimus delays tumor progression in hard-to-treat neuroendocrine tumors

The results of a large Phase-III clinical trial have shown that the drug everolimus delays tumor progression in patients with a hard-to-treat group of rare cancers that affect particular hormone-producing cells.

11 Oct 2010

Fertility concerns of cancer survivors inadequately addressed, study finds

Many cancer survivors experience changes in sexual function that leave them feeling guilty and a longing for intimacy, Australian researchers told at the 35th Congress of the European Society for Medical Oncology (ESMO) in Milan, Italy. The researchers say that these sexuality and fertility concerns are often not adequately addressed by doctors.

11 Oct 2010

Sexual issues a major concern for cancer patients taking new targeted drugs

New drugs that target specific molecular mechanisms of cancer have improved the treatment of cancer patients in recent years, but those benefits may come with a cost to the patient’s sex life, researchers have found. At the 35th Congress of the European Society for Medical Oncology (ESMO) in Milan, Italy, French researchers reported on one of the few studies to investigate the impact of cancer therapy on the sexual functioning of patients.

11 Oct 2010

Early cancer drug trials flawed by inconsistencies in prohibited drug lists, study finds

Researchers in Canada and France have raised concerns about substantial inconsistencies in a basic aspect of the way Phase-I and Phase-II cancer clinical trials are designed.

11 Oct 2010

New phase 2 study shows first-line promise of lung cancer drug PF-299

A new-generation lung cancer drug has shown an impressive ability to prevent disease progression when administered as a first-line treatment in patients with advanced disease, investigators reported at the 35th Congress of the European Society for Medical Oncology (ESMO).

11 Oct 2010

Abiraterone acetate improves survival in metastatic castration-resistant prostate cancer

Patients with metastatic castration-resistant prostate cancer who have progressed after chemotherapy live significantly longer if treated with the drug abiraterone acetate compared to placebo, the results of a large Phase-III clinical trial confirm.

11 Oct 2010

$Pazopanib shows promise in phase-2 trial for relapsed/refractory urothelial cancer$

Pazopanib shows promise in phase-2 trial for relapsed/refractory urothelial cancer

An ongoing Phase-II trial investigating a new, targeted therapy for metastatic urothelial cancer has generated promising early results, Italian researchers reported at the 35th Congress of the European Society for Medical Oncology (ESMO) in Milan, Italy.

11 Oct 2010

Afatinib benefits lung cancer patients whose cancer progressed after treatment with EGFR inhibitors

Lung cancer patients who have already been treated with the EGFR inhibitors erlotinib or gefitinib seem to gain further benefits in terms of progression-free survival and tumor shrinkage when treated with the new drug afatinib, the results of a Phase IIb/III trial show.

11 Oct 2010

Medical Research News

Scripps Research study findings could transform drug development to produce more effective treatments

Researchers develop new method to identify chemical histone modifications

Physical and psychological factors contribute to somatic symptoms: Report

Halozyme Therapeutics to advance core proprietary programs through key clinical inflection points

Working mothers lose favor in a population study

Helmets to prevent rising off-road bike crashes

Insulin resistance increases risk of stroke in non-diabetic patients

Study: Neurons interact to drive decision-making

Balloon kyphoplasty relieves painful spine fractures in patients with metastatic cancer

New targeted therapy adds benefit to erlotinib in some patients with advanced lung cancer

Erlotinib improves progression-free survival as first-line therapy in advanced lung cancer

Identifying subsets of patients who will respond to subsequent lines of chemotherapy

Phase 3 study shows everolimus delays tumor progression in hard-to-treat neuroendocrine tumors

Fertility concerns of cancer survivors inadequately addressed, study finds

Sexual issues a major concern for cancer patients taking new targeted drugs

Early cancer drug trials flawed by inconsistencies in prohibited drug lists, study finds

New phase 2 study shows first-line promise of lung cancer drug PF-299

Abiraterone acetate improves survival in metastatic castration-resistant prostate cancer

Pazopanib shows promise in phase-2 trial for relapsed/refractory urothelial cancer

Afatinib benefits lung cancer patients whose cancer progressed after treatment with EGFR inhibitors

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Scalable, Smart, and Accessible: The Future of Lab Automation

Healthy Beginnings, Hopeful Futures: A Conversation with WHO’s Dr. Allotey

Latest News